A new pilot trial at Northwestern University is asking one of the most important questions in synovial sarcoma treatment: when TCR-T therapy stops working, are the T cells truly gone, or can they be brought back to life? Background: The Promise and the Limit of TCR-T Therapy TCR-T cell therapy represents a major advance for […]
Two New TCR-NK Cell Therapy Trials Now Recruiting for Synovial Sarcoma
Two clinical trials testing TCR-NK cell therapy for advanced synovial sarcoma are now recruiting patients, one in the United States and one in the United Kingdom. Both use donor-derived natural killer cells engineered to target proteins commonly found on synovial sarcoma tumors. What Is TCR-NK Cell Therapy? TCR-NK therapy works differently from the TCR-T cell […]
Why a Melanoma Vaccine Breakthrough Matters for Synovial Sarcoma
Merck and Moderna are making headlines after their personalized mRNA cancer vaccine entered Phase 3 clinical trials for melanoma. For most people, it is an exciting medical story. For the synovial sarcoma community, it is something more personal than that. What the Vaccine Is mRNA-4157, combined with Merck’s immunotherapy pembrolizumab, works by sequencing a patient’s […]
World’s First MAGE-A4-Targeting TCR-NK Therapy Zelluna Doses First Patient in Clinical Trial
Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester, United Kingdom, the largest single-site cancer centre in Europe, marking […]




